Perspective Therapeutics, Inc., was founded in Delaware. The company is a medical technology and radiopharmaceutical company that has pioneered advanced therapeutic applications for systemic cancers. The company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead -212 to deliver powerful α-radiation to cancer cells through specialized targeted peptides. The company is also developing complementary imaging diagnostic technologies that combine the same targeted peptides to provide opportunities for personalized therapy and optimized patient outcomes. This "therapeutic diagnosis" approach enables people to see specific tumors and then treat them, potentially improving efficacy and minimizing toxicity associated with many other types of cancer treatment. The company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering phase 1/2 a imaging and therapeutic trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The company has also developed a proprietary lead-212 generator to ensure isotope availability for clinical trials and commercial operations.